2026年美国临床肿瘤学会（ASCO）年会将于5月29日至6月3日在美国芝加哥举行。作为全球规模最大的肿瘤学研究盛会之一，此次大会云集全球肿瘤学领域的顶尖专家学者，共同探讨和分享最新的研究成果、治疗方法和临床实践经验。目前大会官网已公布摘要标题，【肿瘤资讯】特此整理了本届大会中消化道肿瘤领域的重磅口头报告（Clinical Science Symposium, Oral Abstract Session以及Rapid Oral Abstract Session）的最新研究成果，以飨诸君。
临床科学研讨会（Clinical Science Symposium）
专场名称：ctDNA在临床实践中的应用：从检测到临床决策（ctDNA in Clinical Practice: From Detection to Clinical Decision-Making）
摘要号：102
英文标题：Benefit of adjuvant chemotherapy in resected stage I-IV CRC patients based on ctDNA dynamics across two timepoints: Results from GALAXY study.
中文标题：基于两个时间点ctDNA动态变化评估辅助化疗在I–IV期切除结直肠癌患者中的获益：GALAXY研究结果
讲者：Mitsuru Yokota, MD, PhD
医院/机构：Kurashiki Central Hospital, Japan
专场名称：提升患者话语权：在现代临床试验中选择恰当的以患者为中心的终点指标（Elevating the Patient Voice: Choosing the Right Patient-Centered Endpoints in Modern Clinical Trials）
摘要号：105
英文标题：Patient reported outcomes (PRO) during and after multimodal treatment for resectable esophageal adenocarcinoma in the prospective, randomized, controlled, multicenter phase III ESOPEC trial.
中文标题：ESOPEC研究：前瞻性、随机、对照、多中心III期临床试验中，可切除食管腺癌多模态治疗期间及之后的患者报告结局（PRO）
讲者：Jens Hoeppner, MD
医院/机构：University of Bielefeld, University Medical Center OWL, Campus Hospital Lippe, Germany
专场名称：个性化治疗：靶向肿瘤新抗原（Making It Personal: Targeting Tumor Neoantigens）
摘要号：2509
英文标题：An investigator-initiated phase I study evaluating the safety, tolerability, and preliminary efficacy of a personalized neoantigen mRNA vaccine (XP-004) combined with PD-1 inhibitor as adjuvant therapy in resected pancreatic cancer patients intolerant to chemotherapy.
中文标题：个性化新抗原mRNA疫苗（XP-004）联合PD-1抑制剂用于不耐受化疗的切除胰腺癌辅助治疗的1期研究
讲者：Wei Wang
医院/机构：上海鑫谱生物科技有限公司，中国
摘要号：2511
英文标题：Personalized neoantigen vaccine as adjuvant therapy in high-risk postoperative esophageal carcinoma.
中文标题：个性化新抗原疫苗作为高风险术后食管癌的辅助治疗
讲者：吴明
医院/机构：浙江大学医学院附属第二医院，中国
口头报告（Oral Abstract Session）
专场名称：胃肠道肿瘤——结直肠癌和肛门癌（Gastrointestinal Cancer—Colorectal and Anal）
摘要号：LBA3500
英文标题：Disease-free survival (DFS) and time to recurrence (TTR) with circulating tumor (ct) DNA–based decision for adjuvant treatment in colon cancer stage II (CIRCULATE): An AIO (KRK-0217)/ABCSG trial.
中文标题：CIRCULATE研究：基于ctDNA决策的II期结肠癌辅助治疗的无病生存期（DFS）和复发时间（TTR）结果
讲者：Gunnar Folprecht
医院/机构：Technical University Dresden, Germany
摘要号：3501
英文标题：Informing optimal duration of adjuvant chemotherapy (ACT) in resected stage I-IV colorectal cancer (CRC) based on early circulating tumor DNA (ctDNA) dynamics.
中文标题：基于早期ctDNA动态变化指导I-IV期切除结直肠癌辅助化疗的最佳时长
讲者：Eiji Oki, MD, PhD, FACS
医院/机构：Kyushu University Hospital, Japan
摘要号：3502
英文标题：Observation versus maintenance PD-1 inhibitor therapy after clinical complete response in dMMR/MSI-H colorectal cancer managed with non-operative management: A multicentre cohort study.
中文标题：非手术治疗的dMMR/MSI-H结直肠癌临床完全缓解后观察对比维持PD-1抑制剂治疗的多中心队列研究
讲者：高晓航
医院/机构：中山大学肿瘤防治中心，中国
摘要号：LBA3503
英文标题：BREAKWATER: Progression-free and overall survival analyses of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC).
中文标题：BREAKWATER研究：一线康奈非尼+西妥昔单抗+FOLFIRI治疗BRAF V600E突变转移性结直肠癌的PFS和OS分析
讲者：Scott Kopetz
医院/机构：MD Anderson Cancer Center, USA
摘要号：3504
英文标题：SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated MSS, BRAFV600E metastatic colorectal cancer (mCRC).
中文标题：SWOG S2107：康奈非尼+西妥昔单抗±纳武利尤单抗治疗经治MSS、BRAF V600E突变转移性结直肠癌的随机II期试验
讲者：Van K. Morris, MD
医院/机构：The University of Texas MD Anderson Cancer Center, USA
摘要号：3505
英文标题：Phase 3 trial of trastuzumab rezetecan vs standard of care (SOC) for chemotherapy-refractory, HER2-positive, advanced colorectal cancer (CRC).
中文标题：瑞康曲妥珠单抗对比标准治疗用于化疗难治性HER2阳性晚期结直肠癌的III期试验
讲者：李进
医院/机构：中国药科大学附属上海高博肿瘤医院，中国
摘要号：LBA3506
英文标题：Adjuvant hepatic arterial infusion pump chemotherapy with floxuridine for patients with resectable colorectal liver metastases and a low clinical risk score: A randomized controlled trial—The PUMP trial.
中文标题：PUMP试验：辅助性肝动脉灌注泵化疗用于低临床风险评分的可切除结直肠癌肝转移患者的随机对照试验
讲者：Bas Groot Koerkamp, MD, PhD
医院/机构：Erasmus MC Cancer Institute, Netherlands
摘要号：3507
英文标题：Structured exercise program following adjuvant chemotherapy for colon cancer: A cost-utility analysis of the CHALLENGE trial.
中文标题：CHALLENGE试验：结肠癌辅助化疗后结构化运动项目的成本效用分析
讲者：Kelvin K. Chan, MD, PhD
医院/机构：Sunnybrook Health Sciences Centre, Canada
摘要号：LBA3508
英文标题：Adjuvant aspirin for stage III colorectal cancer after curative resection: Primary analysis of the randomized double-blind placebo-controlled phase III trial (EPISODE-III: JCOG1503C).
中文标题：EPISODE-III: JCOG1503C研究：阿司匹林用于III期结直肠癌根治术后辅助治疗的随机双盲对照III期试验主要分析
讲者：Atsuo Takashima
医院/机构：National Cancer Center Hospital, Japan
专场名称：胃肠道肿瘤——胃食管癌、胰腺癌及肝胆癌（Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary）
摘要号：LBA4000
英文标题：Efficacy and safety results from EMERALD-3: A phase 3, randomized study of tremelimumab plus durvalumab with or without lenvatinib combined with transarterial chemoembolization (TACE) in participants (pts) with unresectable embolization-eligible hepatocellular carcinoma (eeHCC).
中文标题：EMERALD-3研究：双免联合±仑伐替尼联合TACE治疗不可切除肝细胞癌的III期随机研究结果
讲者：Ghassan K. Abou-Alfa, MD, PhD, MBA, JD, FASCO
医院/机构：Memorial Sloan Kettering Cancer Center; Weill Medical College at Cornell University, USA
摘要号：4001
英文标题：Camrelizumab (C) plus rivoceranib (R) with transarterial chemoembolization (TACE) vs TACE alone in unresectable hepatocellular carcinoma (uHCC): A randomized, phase 3 trial.
中文标题：卡瑞利珠单抗联合阿帕替尼+TACE对比单纯TACE治疗不可切除肝细胞癌的随机III期试验
讲者：荚卫东
医院/机构：中国科学技术大学附属第一医院（安徽省立医院），中国
摘要号：4002
英文标题：IMbrave251: Final analysis of atezolizumab (atezo) + lenvatinib (lenva) or sorafenib (sora) vs lenva or sora alone in locally advanced or metastatic hepatocellular carcinoma (LA/mHCC) previously treated with atezo and bevacizumab (bev).
中文标题：IMbrave251研究：阿替利珠单抗联合仑伐替尼/索拉非尼单药治疗阿替利珠单抗+贝伐珠单抗经治后的HCC最终分析
讲者：待定
医院/机构：待定
摘要号：4003
英文标题：First-line treatment of QLS31905 plus chemotherapy in patients with pancreatic cancer and gastric cancer: Data from a phase 1b/2 study.
中文标题：QLS31905联合化疗一线治疗胰腺癌和胃癌患者：1b/2期研究数据
讲者：张小田
医院/机构：北京大学肿瘤医院，中国
摘要号：4004
英文标题：A randomized phase II dose optimization study for alveltamig (ZG006), a trispecific T-cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with refractory neuroendocrine carcinoma (ZG006-003).
中文标题：一项评估alveltamig（ZG006，一种靶向DLL3/DLL3/CD3的三特异性T细胞衔接器）用于难治性神经内分泌癌患者单药治疗的随机II期剂量优化研究（ZG006-003）
讲者：徐建明
医院/机构：中国人民解放军总医院，中国
摘要号：4006
英文标题：Nivolumab plus ipilimumab combined with chemotherapy as first-line treatment for HER2-negative unresectable advanced or recurrent gastric/gastroesophageal junction cancer: A randomized phase 3 trial (ATTRACTION-6).
中文标题：ATTRACTION-6研究：纳武利尤单抗联合伊匹木单抗加化疗一线治疗HER2阴性不可切除晚期或复发性胃/胃食管交界处癌的随机3期试验
讲者：Do-Youn Oh
医院/机构：Seoul National University College of Medicine, South Korea
摘要号：4007
英文标题：ONO-4578 combined with nivolumab (NIVO) and chemotherapy (chemo) as first-line (1L) treatment for patients with HER2-negative unresectable advanced or recurrent (adv/rec) gastric/gastroesophageal junction cancer (G/GEJ): A randomized, double-blind, phase 2 trial (ONO-4578-08).
中文标题：ONO-4578联合纳武利尤单抗和化疗一线治疗HER2阴性不可切除晚期或复发性胃/胃食管交界处癌的随机、双盲、2期试验（ONO-4578-08）
讲者：Sung Hee Lim
医院/机构：Samsung Medical Center, South Korea
摘要号：4008
英文标题：Izalontamab brengitecan (iza-bren) versus chemotherapy in patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC): A multicenter, randomized, open-label, phase III study.
中文标题：Iza-bren对比化疗治疗复发或转移性食管鳞癌的随机、开放标签、多中心III期研究
讲者：鲁智豪
医院/机构：北京大学肿瘤医院，中国
专场名称：发展治疗学—免疫疗法（Developmental Therapeutics—Immunotherapy）
摘要号：2508
英文标题：Objective response rates with Ori-C101, an armored GPC3-directed CAR-T, in heavily pretreated advanced HCC: Updated results from the phase Ib BEACON study.
中文标题：新型“装甲化”GPC3靶向CAR-T细胞制剂Ori-C101治疗经多线治疗的晚期肝细胞癌的客观缓解率：Ib期BEACON研究的更新结果
讲者：樊嘉
医院/机构：复旦大学附属中山医院，中国
快速口头报告（Rapid Oral Abstract Session）
专场名称：胃肠道肿瘤——结直肠癌和肛门癌（Gastrointestinal Cancer—Colorectal and Anal）
摘要号：LBA3509
英文标题：A phase III, randomized, open-label study of tunlametinib plus vemurafenib versus investigator's choice of therapy in patients with previously treated BRAFV600E-mutant metastatic colorectal cancer.
中文标题：Tunlametinib联合维莫非尼对比研究者选择疗法治疗经治BRAFV600E突变转移性结直肠癌的III期研究
讲者：许婷
医院/机构：北京大学肿瘤医院，中国
摘要号：3510
英文标题：Onvansertib plus standard-of-care chemotherapy plus bevacizumab in first-line RAS-mutated metastatic colorectal cancer (mCRC): Interim results from the phase 2 randomized CRDF-004 trial.
中文标题：Onvansertib加标准化疗联合贝伐珠单抗一线治疗RAS突变转移性结直肠癌（mCRC）：随机2期CRDF-004试验的中期结果
讲者：Heinz-Josef Lenz, MD
医院/机构：University of Southern California Norris Comprehensive Cancer Center, USA
摘要号：3511
英文标题：Circulating tumor DNA (ctDNA) clearance as an early indicator of sotorasib + panitumumab efficacy and prognosis in KRAS G12C–mutated colorectal cancer (mCRC): Results from phase 3 CodeBreaK 300.
中文标题：循环肿瘤DNA（ctDNA）清除作为sotorasib联合帕尼单抗在KRAS G12C突变结直肠癌（mCRC）中疗效和预后的早期指标：3期CodeBreaK 300研究结果
讲者：Filippo Pietrantonio, MD
医院/机构：Fondazione IRCCS Istituto Nazionale dei Tumori, Italy
摘要号：3512
英文标题：Phase III CR-SEQUENCE trial of FOLFOX+panitumumab followed by FOLFIRI+bevacizumab (SEQ1) versus FOLFOX + bevacizumab followed by FOLFIRI + panitumumab (SEQ2) in previously untreated RAS wild-type, left-sided, unresectable metastatic colorectal cancer.
中文标题：3期CR-SEQUENCE试验：FOLFOX+帕尼单抗序贯FOLFIRI+贝伐珠单抗（SEQ1）对比FOLFOX+贝伐珠单抗序贯FOLFIRI+帕尼单抗（SEQ2）治疗初治RAS野生型、左侧不可切除转移性结直肠癌
讲者：Ramon Salazar, MD, PhD
医院/机构：Institut Català d'Oncologia (ICO), Spain
摘要号：3513
英文标题：Development of a computational histology artificial intelligence (CHAI)–powered predictive biomarker for first-line chemotherapy intensification in metastatic colorectal cancer (mCRC) and validation in prospective randomized phase III trials (RCT).
中文标题：开发基于计算组织学人工智能（CHAI）的预测生物标志物，用于转移性结直肠癌（mCRC）一线化疗强化的决策，并在前瞻性随机3期试验中验证
讲者：Paolo Ciraci, MD
医院/机构：Azienda Ospedaliera Universitaria Pisana / University of Pisa, Italy
摘要号：3514
英文标题：Phase I study of intraperitoneal fast-manufactured IL-9-secreting CEACAM5-targeted CAR-T cells in advanced colorectal cancer with peritoneal metastases.
中文标题：腹腔内注射快速制备的IL-9分泌型CEACAM5靶向CAR-T细胞治疗伴腹膜转移晚期结直肠癌的I期研究
讲者：张航宇
医院/机构：浙江大学医学院附属第一医院，中国
摘要号：3516
英文标题：Real-world outcomes and circulating tumor DNA (ctDNA) dynamics in patients (pts) with microsatellite instability–high (MSI-H) metastatic colorectal cancer (CRC) treated with immune checkpoint inhibitors (ICI).
中文标题：接受免疫检查点抑制剂（ICI）治疗的微卫星不稳定高（MSI-H）转移性结直肠癌（CRC）患者的真实世界结局和循环肿瘤DNA（ctDNA）动态变化
讲者：Hannah Ruth Robinson, MD
医院/机构：University of Colorado Anschutz School of Medicine, USA
专场名称：胃肠道肿瘤——胃食管癌、胰腺癌及肝胆癌（Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary）
摘要号：4009
英文标题：Neoadjuvant/adjuvant serplulimab vs. placebo combined with chemotherapy for PD-L1–positive gastric cancer: A randomized, double-blind, multicenter phase 3 study.
中文标题：新辅助/辅助斯鲁利单抗对比安慰剂联合化疗治疗PD-L1阳性胃癌：一项随机、双盲、多中心3期研究
讲者：沈琳
医院/机构：北京大学肿瘤医院，中国
摘要号：4010
英文标题：Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): PD-L1 subgroup analysis from HORIZON-GEA-01.
中文标题：HORIZON-GEA-01研究的PD-L1亚组分析：zanidatamab+化疗±替雷利珠单抗一线治疗HER2阳性局部晚期或转移性胃食管腺癌（mGEA）
讲者：待定
医院/机构：待定
摘要号：4011
英文标题：A phase 2 pivotal study of savolitinib in patients with MET-amplified gastric cancer or gastroesophageal junction adenocarcinomas.
中文标题：赛沃替尼（savolitinib）治疗MET扩增的胃癌或胃食管交界处腺癌患者的2期关键研究
讲者：彭智
医院/机构：北京大学肿瘤医院，中国
摘要号：4012
英文标题：Randomized phase II trial of olaparib and pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2) mutations: SWOG S2001.
中文标题：SWOG S2001：奥拉帕利联合帕博利珠单抗对比奥拉帕利单药作为种系BRCA1/2突变转移性胰腺癌患者维持治疗的随机2期试验
讲者：Vincent Chung
医院/机构：City of Hope Comprehensive Cancer Center, USA
摘要号：4013
英文标题：Results from a phase 2a study of atebimetinib in combination with mGnP in advanced or metastatic pancreatic cancer.
中文标题：atebimetinib联合mGnP治疗晚期或转移性胰腺癌的2a期研究结果
讲者：待定
医院/机构：待定
摘要号：4014
英文标题：Nilvanstomig (ZG005), an anti-PD-1/TIGIT bispecific antibody, plus bevacizumab vs. sintilimab plus bevacizumab biosimilar as first-line therapy for advanced hepatocellular carcinoma: A randomized, multi-center, phase II trial.
中文标题：抗PD-1/TIGIT双特异性抗体nilvanstomig（ZG005）联合贝伐珠单抗对比信迪利单抗联合贝伐珠单抗生物类似药一线治疗晚期肝细胞癌：一项随机、多中心2期试验
讲者：吴泓
医院/机构：四川大学华西医院，中国
摘要号：4015
英文标题：Tegavivint, a downstream Wnt/β-catenin inhibitor: Dose-finding results from a phase 1/2 trial in advanced hepatocellular carcinoma (aHCC).
中文标题：下游Wnt/β-catenin抑制剂tegavivint在晚期肝细胞癌（aHCC）中1/2期试验的剂量探索结果
讲者：David Hsieh
医院/机构：UT Southwestern Medical Center, USA
摘要号：4016
英文标题：A phase Ib/II trial of first-line trastuzumab, nivolumab, gemcitabine, and cisplatin in HER2-positive biliary tract cancer (HERBOT): A multi-institutional study from the Korean Cancer Study Group.
中文标题：HERBOT：一线曲妥珠单抗、纳武利尤单抗、吉西他滨和顺铂治疗HER2阳性胆道癌的Ib/II期试验（来自韩国癌症研究组的多机构研究）
讲者：Choong-kun Lee, MD, PhD
医院/机构：Yonsei Cancer Center, Yonsei University College of Medicine, South Korea
摘要号：4017
英文标题：Pemigatinib for untreated unresectable/metastatic cholangiocarcinoma (mCCA) with fibroblast growth factor receptor-2 (FGFR2) rearrangement: Phase 3 FIGHT-302 results.
中文标题：FIGHT-302结果：培米替尼治疗伴有FGFR2重排的初治不可切除/转移性胆管癌（mCCA）的3期研究
讲者：Tanios S. Bekaii-Saab, MD, FASCO
医院/机构：Mayo Clinic Arizona, USA
注：ASCO官方摘要将持续更新，本文信息仅供参考，最新内容请以 ASCO 官网发布为准，如有疏漏，欢迎补充指正。
排版编辑：肿瘤资讯-Skye
苏公网安备32059002004080号
